International Clinical Trial: Olaparib tablets 150 mg bioequivalence study in patients who are already receiving a stable dose

Geneva, March 20 -- International Clinical Trials Registry received information related to the study (CTRI/2026/02/104577) titled 'Olaparib tablets 150 mg bioequivalence study in patients who are already receiving a stable dose' on Feb. 24.

Study Type: BA/BE

Study Design: Randomized, Crossover Trial Method of generating randomization sequence:Other Method of allocation concealment:Centralized Blinding and masking:Open Label

Primary Sponsor: M/s Hetero Labs Limited

Condition: Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Intervention: Intervention1: Olaparib tablets 150 mg : The randomized Participants will receive the Test product in a crossover manner as per the randomization schedule. Each parti...